Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data

[1]  P. Backeljauw,et al.  PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope® (somatropin) treatment in children: update on the United States cohort , 2021, Journal of pediatric endocrinology & metabolism : JPEM.

[2]  R. Murray,et al.  Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from the PATRO Adults study , 2020, Therapeutic advances in endocrinology and metabolism.

[3]  R. Murray,et al.  No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study , 2019, BMC Endocrine Disorders.

[4]  M. Polak,et al.  Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program , 2019, The Journal of clinical endocrinology and metabolism.

[5]  M. Maghnie,et al.  Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program , 2018, The Journal of clinical endocrinology and metabolism.

[6]  S. Kirsch,et al.  Growth hormone treatment of Canadian children: results from the GeNeSIS phase IV prospective observational study. , 2018, CMAJ open.

[7]  J. Wit,et al.  Growth hormone — past, present and future , 2018, Nature Reviews Endocrinology.

[8]  Paul Saenger,et al.  Ten years of biosimilar recombinant human growth hormone in Europe , 2017, Drug design, development and therapy.

[9]  A. Swerdlow,et al.  Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study , 2017, The Journal of clinical endocrinology and metabolism.

[10]  中山 優吏佳.  Cincinnati Children’s Hospital Medical Centerでの海外実習を終えて , 2017 .

[11]  D. Dunger,et al.  Baseline Characteristics and Gender Differences in Prepubertal Children Treated with Growth Hormone in Europe, USA, and Japan: 25 Years' KIGS® Experience (1987-2012) and Review , 2016, Hormone Research in Paediatrics.

[12]  L. Sävendahl,et al.  Is safety of childhood growth hormone therapy related to dose? Data from a large observational study. , 2016, European journal of endocrinology.

[13]  D. Dunger,et al.  GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults , 2015, European journal of endocrinology.

[14]  L. Deeb,et al.  Persistence with growth hormone therapy in pediatric patients , 2014 .

[15]  V. Popović,et al.  GH therapy and cancer risk in hypopituitarism: what we know from human studies. , 2013, European journal of endocrinology.

[16]  M. Szalecki,et al.  Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® in children requiring growth hormone treatment , 2013, Therapeutic advances in endocrinology and metabolism.

[17]  H. Christesen,et al.  Comparison of response to 2-years’ growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies , 2012, International Journal of Pediatric Endocrinology.

[18]  N. Speybroeck,et al.  Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. , 2012, The Journal of clinical endocrinology and metabolism.

[19]  A. Klein.  The first subsequent entry biologic authorized for market in Canada: the story of Omnitrope, a recombinant human growth hormone. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[20]  F. Darendeliler,et al.  Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). , 2010, The Journal of pediatrics.

[21]  K. Parker,et al.  Long-term safety of recombinant human growth hormone in children. , 2010, The Journal of clinical endocrinology and metabolism.

[22]  P. Saenger,et al.  Safety of Growth Hormone Treatment in Children Born Small for Gestational Age: The US Trial and KIGS Analysis , 2006, Hormone Research in Paediatrics.